An immune-active tumor microenvironment favors clinical response to ipilimumab.

Ji, Rui-Ru; Chasalow, Scott D; Wang, Lisu; Hamid, Omid; Schmidt, Henrik; Cogswell, John; Alaparthy, Suresh; Berman, David; Jure-Kunkel, Maria; Siemers, Nathan O; Jackson, Jeffrey R; Shahabi, Vafa

Ji, Rui-Ru; Chasalow, Scott D; Wang, Lisu; Hamid, Omid; Schmidt, Henrik; Cogswell, John; Alaparthy, Suresh; Berman, David; Jure-Kunkel, Maria; Siemers, Nathan O; Jackson, Jeffrey R; Shahabi, Vafa.

Affiliation

Ji RR; Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, USA.

Cancer Immunol Immunother ; 61(7): 1019-31, 2012 Jul.

Article in En | MEDLINE | ID: mdl-22146893

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/therapeutic use; Melanoma/drug therapy; Skin Neoplasms/drug therapy; Antibodies, Monoclonal/immunology; Antineoplastic Agents/immunology; Biopsy; Gene Expression/drug effects; Gene Expression Profiling; Humans; Ipilimumab; Lymphocytes, Tumor-Infiltrating/immunology; Melanoma/genetics; Melanoma/immunology; Melanoma/pathology; Neoplasm Metastasis; Neoplasm Staging; Skin Neoplasms/genetics; Skin Neoplasms/immunology; Skin Neoplasms/pathology; Survival Analysis; Tumor Microenvironment/immunology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Melanoma / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Clinical_trials Limits: Humans Language: En Journal: Cancer Immunol Immunother Journal subject: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Year: 2012 Document type: Article Affiliation country: United States Country of publication: Germany

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google